Engineered Immune Cells Promoting Thanotransmission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face challenges in effectively promoting programmed cell death in cancer cells, limiting their ability to induce significant immune responses and tumor reduction.
Innovation Solution
Engineered immune cells expressing heterologous polynucleotides that promote thanotransmission, equipped with chimeric antigen receptors and signal transduction domains, are used to induce cell turnover pathways such as necroptosis, apoptosis, and pyroptosis in target cells, enhancing immune responses and tumor control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies are used to promote programmed cell death in cancer cells, then immune response is activated, but the effectiveness is limited and tumor reduction is insufficient
Solution Approach 1:
The patent employs composite cell death pathways by combining multiple death modalities (apoptosis, necroptosis, pyroptosis, ferroptosis) within a single immunotherapy approach. Engineered immune cells express multiple death domain proteins (FADD, RIPK3, Gasdermin E, PTGS2) that activate different cell death pathways simultaneously, creating a synergistic effect that overcomes the limitations of single-pathway approaches and significantly enhances tumor cell killing efficiency
Solution Approach 2:
The patent modifies the cell death induction mechanism by changing the molecular parameters of immune cells through genetic engineering. Immune cells are engineered to express heterologous polypeptides (FADD, RIPK3, Gasdermin E, PTGS2) that alter the cell death pathway parameters, enabling them to induce multiple types of programmed cell death in cancer cells rather than relying on conventional single-pathway mechanisms
2Reliability
If engineered immune cells express multiple thanotransmission polypeptides, then cell death pathways are enhanced, but device complexity increases
Solution Approach 1:
The patent creates universal engineered immune cells that can induce multiple types of cell death (apoptosis, necroptosis, pyroptosis, ferroptosis) through a single multi-functional design. The engineered immune cells express a panel of death domain proteins that collectively provide broad-spectrum cell death induction capability, allowing one cell type to perform multiple death-inducing functions rather than requiring separate engineered cell lines for each pathway
Solution Approach 2:
The patent merges multiple cell death pathways into a unified therapeutic approach by co-expressing multiple death domain proteins (FADD for apoptosis, RIPK3 for necroptosis, Gasdermin E for pyroptosis, PTGS2 for ferroptosis) in the same engineered immune cells. This consolidation allows simultaneous activation of multiple death pathways through a single cell product, reducing the complexity of producing and managing multiple separate cell therapies
Data Source
AI summary
In certain aspects, the disclosure relates to an immune cell that has been engineered to comprise one or more heterologous polynucleotides that promote thanotransmission by the immune cell. The immune cell may also comprise one or more nucleic acid sequences that encode a chimeric antigen receptor (CAR). Methods of promoting thanotransmission, promoting immune response, and treating cancer using the engineered immune cells are also disclosed.